85 patents
Utility
Treating Patients Harboring an Isocitrate DEHYDROGENASE-1 (IDH-1) Mutation
30 Mar 23
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 14 Nov 22
Utility
Tetrahydroquinoline Compositions As Bet Bromodomain Inhibitors
2 Mar 23
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
Filed: 23 Jul 21
Utility
Inhibiting Ubiquitin Specific Peptidase 9X
2 Mar 23
The disclosure provides novel chemical compounds useful as inhibitors of ubiquitin specific peptidase 9X (USP9X).
Bruce FOLLOWS, Katherine J. KAYSER-BRICKER, Adam Charles TALBOT, Scot MENTE, Tatiana SHELEKHIN, Anna ERICSSON
Filed: 19 Sep 19
Utility
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
2 Mar 23
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Patrick F. Kelly, Susan Ashwell, Blythe Thomson, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Filed: 21 Mar 22
Utility
Composite conduit formwork structure and method of fabrication
28 Feb 23
The disclosure presents a composite conduit formwork structure which includes a cylindrical outer casing adapted to bond with a cylindrical inner casing which are maintained at a fixed distance apart by a plurality of radial stanchions.
Scott Armstrong
Filed: 10 Nov 20
Utility
Activating Pyruvate Kinase R
23 Feb 23
The disclosure provides novel chemical compounds useful as activators of PKR.
Xiaozhang ZHENG, Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Jian LIN, Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN
Filed: 19 Sep 19
Utility
Inhibiting mutant IDH-1
14 Feb 23
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 16 May 19
Utility
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
31 Jan 23
This disclosure relates to compositions and methods for inhibiting mutant IDH1, useful in treatment of mIDH1 cancers including AML, as well as mIDH1-positive solid tumors such as glioma.
Jian Lin, George P. Luke, Madhu Mondal
Filed: 19 Nov 20
Utility
Reconfigurable composite floor formwork and method of use
3 Jan 23
The disclosure presents a reconfigurable composite floor formwork which defined by a plurality of interlocking fiberglass panels formed into profiles which may be moved and adapted to provide a concrete form for a floor or ceiling.
Scott Armstrong
Filed: 10 Nov 20
Utility
Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
27 Dec 22
Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
Filed: 4 Oct 19
Utility
Composite subgrade formwork and method of use
13 Dec 22
The disclosure presents a formwork system which utilizes Fiber Reinforced Polymer (FRP) panels to create modular segments to form and reinforce concrete subgrade structures.
Scott Armstrong
Filed: 10 Nov 20
Utility
Pyruvate Kinase R (PKR) Activating Compositions
1 Dec 22
The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.
George P. Luke, Suresh Babu
Filed: 18 Sep 20
Utility
Activating Pyruvate Kinase R
1 Dec 22
The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen.
Anna Ericsson, Sanjeev Forsyth, Neal Green, Gary Gustafson, Patrick F. Kelly, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, Madhu Mondal, Maria Ribadeneira, David Richard, Patricia Schroeder, Zhongguo Wang
Filed: 18 Sep 20
Utility
Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
15 Nov 22
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 4 Dec 20
Utility
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
15 Nov 22
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Filed: 23 Nov 20
Utility
Inhibiting Fatty Acid Synthase (Fasn)
6 Oct 22
The present disclosure is directed to inhibitors of FASN.
Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
Filed: 10 Feb 22
Utility
Activating Pyruvate Kinase R
29 Sep 22
The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, JR., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang, Sanjeev Forsyth, Patrick F. Kelly, Madhu Mondal, Maria Ribadeneira, Patricia Schroeder
Filed: 18 Mar 22
Utility
Purinones As Ubiquitin-specific Protease 1 Inhibitors
8 Sep 22
Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin Andrew Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
Filed: 30 Sep 21
Utility
Compositions for activating pyruvate kinase
26 Jul 22
Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
Filed: 2 Oct 20
Utility
Inhibiting mutant IDH-1
5 Jul 22
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 25 Nov 19